Full Press Release Details
Akari Therapeutics Presents Results from the CASCADE
and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics,
Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases,
presented results from the CASCADE and CORONET studies in patients with COVID-19 pneumonia at the American Thoracic Society (ATS) 2022
CASCADE, an observational study in a single United Kingdom hospital,
explored relationships between circulating biomarkers and risk stratification categories in subsets of COVID-19 pneumonia patients. Patients
were clinically stratified as mild, moderate or severe according to degree of respiratory failure on admission and compared to matched
healthy controls. Several biomarkers of inflammation, including complement, were elevated across all patient groups compared to healthy
controls with complement C5a higher in severe patients compared to moderate patients.
The CORONET study evaluated compassionate use of investigational nomacopan
in the treatment of hospitalized COVID-19 pneumonia patients at two centers in the United States. As seen in CASCADE and other studies,
the innate immune system plays a potentially important role in driving the pathology of COVID-19 pneumonia. Nomacopan inhibits complement
C5a and leukotriene B4 (LTB4). Seven patients were treated with a 45mg subcutaneous dose of nomacopan twice (every 12 hours) on the first
day. Subsequently, patients were administered 45mg of subcutaneous nomacopan once daily for 12 days. Prophylactic antibiotics were co-administered
with nomacopan. Six patients who received the full course of treatment with nomacopan in the CORONET study survived and were discharged
from the hospital. One patient who experienced a delay in the initiation of treatment died. No treatment-related adverse effects were
posters are available at http://investor.akaritx.com/news-and-events/presentations.
About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company focused
on developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific
recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity. The Akari pipeline includes two late-stage programs
for bullous pemphigoid (BP) and thrombotic microangiopathy (TMA), as well as earlier stage research and development programs in eye and
lung diseases with significant unmet need. For more information about Akari, please visit akaritx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking statements reflect
our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available
to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected
in or suggested by those forward- looking statements are reasonable, we can give no assurance that the plans, intentions, expectations
or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking
statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company
include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties
of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan
and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional
indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any
other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to
realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties
involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product
candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products
brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks
associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property
rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing
arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases
and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission,
including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking
statements contained in this press release.
For more information
Sukaina Virji/ Maya Bennison
Consilium Strategic Communications